Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is InterMune Inc. Your Next Biotech Buyout?

InterMune  (NASDAQ: ITMN  ) was health care's top performing stock, thanks to positive phase 3 trial results for its lead drug Esbriet in idiopathic pulmonary fibrosis. Shares popped nearly 15% as Esbriet compared favorably with a competing drug also in late-stage develpment, by Boehringer Ingelheim.

This caused a rash of upgrades from Wall Street analysts, who insist InterMune is now a full-fledged takeover target. However, deep-pocketed competitors like Biogen Idec (NASDAQ: BIIB  ) and Bristol-Myers Squibb (NYSE: BMY  ) are lurking with mid-stage drugs using completely different methods of action that could pose a threat to Esbriet's blockbuster potential.

In this episode of Market Check-Up, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss the trial results, IPF drug competition, and ultimately why InterMune investors should be exited about their stock.

Read/Post Comments (0) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2963899, ~/Articles/ArticleHandler.aspx, 9/3/2015 11:16:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,529.50 178.12 1.09%
S&P 500 1,974.56 25.70 1.32%
NASD 4,793.04 43.06 0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ITMN $0.00 Down +0.00 +0.00%
InterMune CAPS Rating: **
BIIB $308.61 Up +4.40 +1.45%
Biogen Idec CAPS Rating: ****
BMY $60.11 Up +0.50 +0.84%
Bristol-Myers Squi… CAPS Rating: ****